Edwards Lifesciences (EW) - Get Report gained more than 6% on Monday after the medical research and device company announced positive results related to its recent aortic valve surgical treatment trial.
Edwards Lifesciences stock gained $10.91 to $190.66 on the New York Stock Exchange after the company on Saturday said its SAPIEN 3 transcatheter aortic valve proved successful in patient trials vs. more traditional open-heart surgery treatment.
"The trial, which compared treatment with the SAPIEN 3 valve to surgery in patients with severe symptomatic aortic stenosis (AS) at low risk of death from surgery, achieved superiority of its primary endpoint at one year," the company said in a statement.
Outcomes between transcatheter aortic valve replacement and open-heart surgery with the SAPIEN 3 valve achieved "a 46% reduction in the event rate for the primary endpoint of the trial, which was a composite of all-cause mortality, all stroke and rehospitalization at one year."
The results were presented on Sunday as part of the late-breaking clinical trials at the American College of Cardiology's 68th Annual Scientific Session in New Orleans. They have also been published online in the New England Journal of Medicine.
Based in Irvine, Calif., Edwards Lifesciences focuses on products and services for structural heart disease, as well as critical care and surgical monitoring.
Will You Have Enough Money to Retire?
Want to learn about retirement planning from some of the nation's top experts? Join TheStreet's Robert "Mr. Retirement" Powell live in New York on April 6 for our Retirement Strategies Symposium. For a limited time, tickets are available for $99 for this full-day event. Check out the agenda, learn about the speakers and sign up here.